Home / Contract Awards / SRI International Lands 2 BARDA Nonclinical Research Service Contracts Worth $90M

SRI International Lands 2 BARDA Nonclinical Research Service Contracts Worth $90M

SRI International has received a pair of contracts worth a combined $90 million to help  the Biomedical Advanced Research and Development Authority assess compounds that have potential to treat people exposed to chemical, biological, radiological or nuclear weapons.

The company said Wednesday that both contracts have a base period of five years and cover nonclinical research services such as pharmacologic analysis and safety testing of various CBRN medical countermeasures.

SRI will work to help the agency transition potential agents from early-stage discovery into clinical trials through a Food and Drug Administration-approved investigational new drug application.

“SRI is pleased to be able to expand our ongoing relationship with BARDA, offering additional testing capabilities to thoroughly evaluate the safety of potential medical countermeasures before they are tested in humans,” said Deborah Bunin, director of molecular toxicology at SRI’s biosciences division.

Brunin will be the principal investigator under a contract to help the agency develop MCMs.

The second contract will involve the application, development and validation of analytical methods used to evaluate the biological distribution and identification of dose levels for drug efficacy.

Carol Green, director of preclinical development at SRI, will lead the second project as principal investigator.

BARDA, a component of the Department of Health and Human Services, develops medical countermeasures as part of efforts to protect civilians from health issues that result from exposure to biological, chemical, radiological and radionuclide agents.

Check Also

MC Dean Wins Potential $98M Navy IDIQ to Build Electronic Security, Emergency Mgmt Systems

M.C. Dean has secured a potential six-year, $98M contract to provide electronic security and emergency management systems for installation on shore facilities operated by the Department of Defense and U.S. federal government.

BGOV: Lockheed F-16, Raytheon Missile Tech In Demand Among Fiscal 2019 FMS Clients

The Raytheon-built (NYSE: RTN) AIM-120C-7 medium air-to-air missile and the F-16 fighter jet from Lockheed Martin (NYSE: LMT) were the most popular weapon systems the U.S. sold to allies in fiscal year 2019 through the foreign military sales program, Bloomberg Government reported Wednesday.